TOI Q3 revenue $136.6M (+37% YoY); adjusted loss narrows, raises FY 2025 guidance

Oncology Institute, Inc.

2025-Q3 EPS reported -$0.49 revenue$360,772,000

Consolidated revenue $136.6M (+36.7% YoY); gross profit $18.9M (+31.7%); net loss $(16.5)M vs $(16.1)M.
Adjusted EBITDA improved to $(3.5)M from $(8.2)M; diluted EPS $(0.14) vs $(0.18) loss per share.
Retail pharmacy revenue $75.9M, set fill records, contributed $12.8M gross profit.
Fee-for-service revenue grew 13% YoY on organic growth in Florida and Oregon.
Full year 2025 guidance raised (specific figures not disclosed in filed excerpt).

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001079973-25-001707
form_type: 8-K
ticker: TOI
cik: 0001799191
company_name: Oncology Institute, Inc.
filed_at: 2025-11-13T23:59:59+00:00
discovered_at: 2026-05-14T18:02:40.493486+00:00
generated_at: 2026-05-16T20:30:07.499763+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: neutral
materiality_score: 0.65
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001079973-25-001707
json_url: https://secwatch.observer/filing/0001079973-25-001707.json
markdown_url: https://secwatch.observer/filing/0001079973-25-001707.md
text_url: https://secwatch.observer/filing/0001079973-25-001707.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1799191/000107997325001707/0001079973-25-001707-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1799191/000107997325001707/toi_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001079973-25-001707

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.